Form 4: Vaxcyte Officer Sells Shares Under 10b5-1 Plan

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, sold 9,743 shares of common stock for approximately $46.69 per share under a pre-arranged trading plan.

Summary

• Harpreet S. Dhaliwal, Chief Technical Operations Officer of Vaxcyte, Inc. (PCVX), sold 9,743 shares of common stock.
• The transaction occurred on December 31, 2025.
• The shares were sold at a weighted-average price of $46.689 per share, with prices ranging from $46.42 to $47.155.
• Following the sale, Dhaliwal beneficially owns 23,928 shares of Vaxcyte common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-scheduled transaction.
• The reported beneficial ownership includes 1 share acquired on November 17, 2025, under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be perceived negatively, the execution under a 10b5-1 plan suggests it's a pre-planned liquidity event rather than a reaction to adverse company news.

Positives

• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate company news, which can reduce concerns about the timing of the sale.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal regarding management's long-term outlook, though it is often for personal financial planning and diversification.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

This filing is a routine insider transaction and does not provide information to analyze broader industry trends or competitors. It reflects an individual's personal financial planning rather than a strategic company move.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a minor signal, but the 10b5-1 plan mitigates concerns about immediate negative implications.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider stock sale.

Key Dates

Recommendation

The insider sale by the Chief Technical Operations Officer, while a disposition of shares, was executed under a pre-arranged 10b5-1 trading plan. This suggests the sale is for personal financial planning rather than a reflection of new, adverse company-specific information. The transaction itself does not provide sufficient new information to alter a fundamental investment thesis for Vaxcyte, Inc., thus a 'hold' recommendation is appropriate.

Keywords

Vaxcyte, PCVX, Insider Trading, Form 4, Stock Sale, Harpreet S. Dhaliwal, Chief Technical Ops Officer, 10b5-1 Plan, Equity Transaction